Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With Post-study Follow-up

NCT03117816 is registered in ClinicalTrials.gov with Philipps University Marburg as lead sponsor.

NCT NCT03117816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03117816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase III, Multicenter Trial With Post-study Follow-up
Lead sponsor
Philipps University Marburg
Phase
Phase 3
Overall status
Completed
Start date
May 4, 2017
Completion date
December 12, 2022
Enrollment
214 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia in remission